Literature DB >> 3100598

Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations.

J Mehta, P Mehta, D Lawson, T Saldeen.   

Abstract

Increased levels of an endogenous inhibitor of tissue-plasminogen activator (t-PA) have been thought to relate to the genesis of acute myocardial ischemia. To examine the role of the rapid inhibitor of t-PA, plasma samples were analyzed from 75 patients with chest pain syndrome undergoing coronary angiography (mean age 57 years), 24 patients with clinically documented coronary artery disease (unstable angina, positive exercise stress test or previous history of myocardial infarction; mean age 58 years) and 15 young normal subjects (mean age 26 years). Plasma t-PA inhibitor levels were similar in age-matched patients regardless of the absence or presence (and degree) of coronary artery disease. Plasma t-PA inhibitor levels correlated significantly with age (r - 0.46, p less than 0.005), suggesting an age-dependent decrease in fibrinolytic activity. Plasma t-PA inhibitor levels also correlated significantly with serum triglyceride levels (r - 0.60, p less than 0.001), but not with coronary risk factors such as serum cholesterol, diabetes, hypertension, serum uric acid levels or body weight. Association of high levels of inhibitor of t-PA with hypertriglyceridemia may be of importance in the development of coronary thrombosis, especially in elderly patients. Nonetheless, this study does not suggest a pathogenic role of t-PA inhibitor in coronary atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3100598     DOI: 10.1016/s0735-1097(87)80373-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  26 in total

1.  Changes in von Willebrand factor and fibrinolysis following a post-exercise cool-down.

Authors:  C M Paton; P R Nagelkirk; A M Coughlin; J A Cooper; G A Davis; H Hassouna; J M Pivarnik; C J Womack
Journal:  Eur J Appl Physiol       Date:  2004-04-20       Impact factor: 3.078

Review 2.  Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

Authors:  Matteo Cesari; Marco Pahor; Raffaele Antonelli Incalzi
Journal:  Cardiovasc Ther       Date:  2010-07-07       Impact factor: 3.023

Review 3.  Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease.

Authors:  D de Bono
Journal:  Br Heart J       Date:  1994-06

4.  Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals.

Authors:  Koji Yamamoto; Kyosuke Takeshita; Takayoshi Shimokawa; Hong Yi; Ken-ichi Isobe; David J Loskutoff; Hidehiko Saito
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

Review 5.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

6.  Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men.

Authors:  A Asplund-Carlson; A Hamsten; B Wiman; L A Carlson
Journal:  Diabetologia       Date:  1993-09       Impact factor: 10.122

Review 7.  Biomarkers of obesity and subsequent cardiovascular events.

Authors:  Salma Musaad; Erin N Haynes
Journal:  Epidemiol Rev       Date:  2007-05-10       Impact factor: 6.222

8.  Relationship of adiposity to the population distribution of plasma triglyceride concentrations in vigorously active men and women.

Authors:  Paul T Williams
Journal:  Atherosclerosis       Date:  2004-06       Impact factor: 5.162

Review 9.  Physical activity and lipoprotein lipid disorders.

Authors:  A Berg; I Frey; M W Baumstark; M Halle; J Keul
Journal:  Sports Med       Date:  1994-01       Impact factor: 11.136

10.  Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia.

Authors:  F Pazzucconi; L Mannucci; L Mussoni; G Gianfranceschi; P Maderna; P Werba; G Franceschini; C R Sirtori; E Tremoli
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.